Shanghai-listed Nanjing Xinjiekou Department Store has made a bid to acquire China Cord Blood Corporation (CCBC), a US-listed blood bank operator backed by KKR, for about RMB6 billion ($966 million).
Tencent has led a $90 million Series C round for Indian clinic management developer and doctor search portal Practo, with participation from Sofina, Google Capital, and others.
Shanghai KingYee, a Chinese mobile healthcare services provider, has completed a RMB221 million ($36 million) Series C round of funding led by Sensegain Investment. SoftBank China Venture Capital (SBCVC) and HighLight Capital also participated.
China-based Hopu Investments and YuanMing Capital have led a $200 million investment in US-based cancer treatment specialist Mevion Medical Systems.
The Riverside Company has acquired in IPAR Rehabilitation, an Australia-based provider of injury prevention and management and rehabilitation services that minimize the impact of workplace injury and illness.
HealthCare Global Enterprises (HCG), a private equity-backed Indian cancer care hospital chain, has filed for an IPO.
India's vast assortment of ethnic groups represents a golden opportunity for MedGenome. The 2,000 groups that inhabit the subcontinent are a treasure trove of information waiting to be harvested and put to work.
GSR Capital and its affiliate Go Scale Capital has raised $1 billion for a cross-border buyout and M&A fund, which it hopes will translate into $5 billion worth of dry powder once debt financing and co-investment are factored in.
GGV Capital has led an extended Series A round of funding for Ypzdw.com, a Chinese online B2B drug retail platform. Existing investor Matrix Partners China also participated.
Sequoia Capital has committed $20 million in Series B funding to Indian genomic diagnostic and research service provider MedGenome.
Healthcare specialist Vivo Capital has led a Series B round of funding for Gengmei, a Chinese cosmetic surgery social networking app, with participation from Sequoia Capital.
KKR has completed its second social enterprise assistance project alongside Impact Investment Exchange Asia (IIX) and its non-profit sister organization Shujog, providing support to Glovax Biotech, which sells affordable vaccines to low to middle income...
FountainVest Partners has led a RMB200 million ($32 million) round of funding for Xingren.com, a Chinese mobile app for doctors to communicate with patients. Existing investors Sequoia Capital and Lightspeed China Partners also participated.
Tiger Global has led a $10.2 million Series B round investment in Indian doctor search app Lybrate.
US early stage investor Founders Fund and Japanese conglomerate Mitsui & Co have together invested JPY620 million ($5.1 million) in Genesis Healthcare, a Tokyo-based start-up that develops genetic testing kits, in exchange for a 6% stake.
Cathay Capital Private Equity has invested an undisclosed sum in Cenexi Group, a French pharmaceutical contract manufacturer.
China-focused food and agriculture specialist Hosen Capital is looking to raise $400 million for its second US dollar-denominated fund.
On the back of reforms and a rising consumer class, China's healthcare sector is expected to see huge growth. Sector specialists have emerged to capitalize on the opportunity. How can they differentiate themselves?
Australian cancer and cardiovascular treatment provider GenesisCare, which is owned by KKR, has bought cancer center manager Cancer Partners UK from its private equity backer, Apposite Capital.
China VC firm Qiming Venture Partners has promoted healthcare specialist William Hu to managing partner with immediate effect.
Australian life sciences specialists Brandon Capital Partners and GBS Ventures will exit local drug developer Spinifex Pharmaceuticals after Novartis agreed to buy the business for $200 million in cash plus unspecified earn-outs.
Roger Hu, a director at Matrix Partners China, has teamed up with Yi Zheng, formerly vice president at Chinese dating app Momo, to launch a renminbi-denominated early-stage fund.
Crescent Capital Partners has agreed to acquire the Australian pathology operations of Healthscope for A$105 million ($80.8 million).